# How an endometriosis study tested two triptorelin preparations

- Article ID: research-404
- Product: Triptorelin GnRH (triptorelin-gnrh-502)
- Canonical page: https://heritagebiolabs.com/research-library/articles/404-how-an-endometriosis-study-tested-two-triptorelin-preparations
- Product collection: https://heritagebiolabs.com/research-library/products/triptorelin-gnrh
- Product page: https://heritagebiolabs.com/product/triptorelin-gnrh-502
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides consist of short amino-acid chains held by peptide bonds, and some can alter how much of another hormone the body makes. Triptorelin is a synthetic ten-amino-acid agonist of the receptor for gonadotropin-releasing hormone, or GnRH. Sustained exposure can lower ovarian estrogen production. A 2026 study in China asked whether an acetate microsphere preparation, in which the drug is carried in small particles, suppressed estradiol about as well as an established triptorelin acetate comparator in people with endometriosis. [1, 2]

The double-blind phase III trial enrolled 392 patients across 47 centers. Each group received an active triptorelin formulation. The main outcome was the proportion whose estradiol fell below the study threshold. At the primary assessment, about 97 percent of participants included in the analysis met that endpoint with the microspheres and about 98 percent did with the comparator. The researchers used a non-inferiority design, which sets the maximum acceptable difference before the trial. The uncertainty around the observed difference stayed within that predefined margin. [1]

Participants in both groups reported lower scores for menstrual pain and pelvic pain outside menstruation compared with their own starting scores, with no statistically clear difference between groups. The proportion reporting adverse drug reactions was also similar. The study found a difference in how soon menstruation returned after treatment ended. That is a distinct outcome from estradiol suppression, and the main result applies to the hormone outcome that the investigators chose in advance. [1]

Comparing two active preparations answers a question about how they perform relative to each other. It leaves the size of any difference versus no treatment outside this experiment. The study was conducted with specific products in China. The two U.S. product labels cited here list advanced prostate cancer and central precocious puberty as their respective approved uses. [1, 2, 3]

## Sources

1. Zhao AM et al. Phase III randomized noninferiority trial of two triptorelin acetate formulations for endometriosis. Zhonghua Fu Chan Ke Za Zhi (2026-01-25). <https://pubmed.ncbi.nlm.nih.gov/41611266/>
2. Verity Pharmaceuticals Inc. TRELSTAR (triptorelin pamoate for injectable suspension), for intramuscular use. DailyMed (label effective 2026-06-30). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3>
3. Azurity Pharmaceuticals, Inc. TRIPTODUR (triptorelin) for extended-release injectable suspension, for intramuscular use. DailyMed (label updated 2025-09-14). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f41380e7-b830-432d-a5f5-a872932f107e>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 081 - Triptorelin GnRH.docx; article 404; content SHA-256 af9323c1dd9886a563f528dd2c79c5b7b09e336e70ca7358a66a3b80e2d93e85.
